pp 1–4 | Cite as

Delivering on the Promise of Biosimilars

  • Arnold G. VultoEmail author


Fifteen years of experience with biosimilar evaluation in Europe and advancement in the science behind biological medicines, provides a timely moment to open up debate as to whether the requirements for biosimilar approval could be further tailored. Further optimizing of data requirements to truly decisional information will allow to continuously deliver on the promise of biosimilars, providing benefits for patients and society.



AGV would like to thank Liese Barbier (MSc Pharmacy; PhD researcher, KU Leuven) for the stimulating discussions and Michelle Derbyshire ( for linguistic review.

Compliance with Ethical Standards


No funding relevant to this commentary was received.

Conflict of interest

AGV is one of the founders of the Research Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund) and is involved in consulting, advisory work and speaking engagements for a number of companies, i.e. AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Novartis, Sandoz, and Boehringer Ingelheim.


  1. 1.
    IQVIA. The impact of biosimilar competition in Europe. Quintiles IMS. 2018;2018:33.Google Scholar
  2. 2.
    IMS. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets introduction. IMS Inst Healthc Informatics. 2016;2016:40.Google Scholar
  3. 3.
    Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019. Scholar
  4. 4.
  5. 5.
    Harston A. FDA’s biosimilar approvals accelerate in 2018: how the US compares to Europe on biosimilar approvals and products in the pipeline. 2019. Accessed 13 Sep 2019.
  6. 6.
    European Medicines Agency. ICH Topic Q5 E Comparability of biotechnological/biological products. 2005.Google Scholar
  7. 7.
    Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.CrossRefGoogle Scholar
  8. 8.
    Webster CJ, Wong AC, Woollett GR. An efficient development paradigm for biosimilars. BioDrugs. 2019. Scholar
  9. 9.
    Planinc A, Dejaegher B, Vander Heyden Y, Viaene J, Van Praet S, Rappez F, et al. Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab. Eur J Hosp Pharm. 2017;24:286–92.CrossRefGoogle Scholar
  10. 10.
    Eric Sagonowsky. AbbVie’s massive Humira discounts are stifling Netherlands biosimilars: report|FiercePharma. 2019. Accessed 13 Sep 2019.
  11. 11.
    Sy Mukherjee. Protect at all costs: how the maker of the world’s bestselling drug keeps prices sky-high. Fortune. 2019. Accessed 13 Sep 2019.
  12. 12.
    Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78:463–78.CrossRefGoogle Scholar
  13. 13.
    Barbier L, Ebbers H, Simoens S, Declerck P, Vulto A, Huys I. The safety of switching between reference biopharmaceuticals and biosimilars: a systematic review. Value Heal. 2018;2018:21. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinical Pharmacology and PharmacotherapyKU LeuvenLeuvenBelgium
  2. 2.Hospital Pharmacy, ErasmusMCRotterdamThe Netherlands

Personalised recommendations